Arcus Biosciences (RCUS) Current Deferred Revenue (2017 - 2026)

Arcus Biosciences' Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $79.0 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 72.85% year-over-year to $79.0 million; the TTM figure through Mar 2026 stood at $79.0 million (down 72.85% YoY), while the FY2025 annual figure was $78.0 million, down 75.55% from the prior year.
• Current Deferred Revenue was $79.0 million for Q1 2026 at Arcus Biosciences, up from $78.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $327.0 million in Q2 2024 to a low of $35.0 million in Q2 2023.
• Historically, Current Deferred Revenue has averaged $129.2 million across 5 years, with a median of $100.0 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue surged 834.29% in 2024, then tumbled 75.55% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $97.0 million in 2022, then plunged by 63.92% to $35.0 million in 2023, then jumped by 811.43% to $319.0 million in 2024, then sank by 75.55% to $78.0 million in 2025, then gained by 1.28% to $79.0 million in 2026.
• The last three Current Deferred Revenue figures came in at $79.0 million (Q1 2026), $78.0 million (Q4 2025), and $52.0 million (Q3 2025), per Business Quant data.